Ceci est une version HTML d'une pièce jointe de la demande d'accès à l'information 'TTIP lobbying'.




Ref. Ares(2015)2574673 - 19/06/2015
Ref. Ares(2016)6036878 - 20/10/2016
EUROPEAN COMMISSION 
Directorate-General for Trade 
 
  Directorate F -  WTO, Legal Affairs & Trade in Goods 
Unit F3: Tariff and Non-Tariff Negotiations, Rules of Origin 
 
 
 
AMCHAM EU PLENARY MEETING 
Medical Devices 
Tuesday 16 June 2015, Brussels 
 
Key note speaker: 
Thomas Huszak – Head of Cabinet of Commissioner Elzbieta BIENKOWSKA  
Panellists:  
•  Céline Bourguignon, Director, Worldwide Government Affairs & Policy, Johnson & 
Johnson 
• 
Senior Research Fellow, CEPS  
• 
Administrator, Tariff and Non-Tariff Negotiations, Rules of Origin 
Unit, DG Trade  
 
Summary: 
Thomas Huszak opened the plenary meeting by mentioning that on 26 September 2012, the 
European Commission adopted a Proposal for a Regulation of the European Parliament and of 
the Council on medical devices and in vitro diagnostic medical devices aiming to ensure that 
patients can reap benefits of safe and innovative products. On 18 and 19 June 2015 the 
Council (Employment, Social Policy, Health and Consumer Affairs Council) will be called on 
to agree its stance on the two draft regulations. Commission hopes that a compromise is 
reached as it is important that the regulations are finally adopted. There are a number of 
challenges and opportunities faced by the medical devices sector such as demographic factors 
(e.g. ageing population, increase rate of chronic diseases), economic factors (pressure on 
public health budgets) and emerging technologies (for the prevention and monitoring of 
diseases). Enterprises need to have a solid legal framework and to get support to growth and 
remain competitive.  He highlighted some factors in the revised draft Regulations of 
importance for the MedTech sector: harmonized rules on reprocessing of single used medical 
devices, proper functioning of notified bodies and conformity assessment, clinical 
investigations aligned with international guidance as well as reinforced market surveillance 
and governance.  

 
Céline Bourguignon continued the discussions by presenting the business perspectives of 
medical devices within TTIP. The economic importance of the MedTech sector was 
highlighted: 25 000 companies of which 95% are SMSs, 575 000 employees and total sales of 
around €100 billion. Johnson & Johnson supports the regulatory convergence between the EU 
and the US. The importance of the implementation of the UDI system, the need for RPS and a 
formal recognition of QMS were highlighted. A study on the EU medical device approval 
safety assessment conducted by Boston Consulting Group in 2011 revealed there is no 
significant difference in safety between the EU-US systems. Johnson and Johnson calls on EU 
for an offensive agenda on medical devices in TTIP leading to significant cost savings for the 
industry by means of cutting red-tape and over-regulation. 
 
 pointed out that there are problems arising from several 
misunderstandings among public opinion on TTIP. Public opinion is focusing on less 
important elements of TTIP that are possibly even not in the TTIP negotiation agenda. While 
a number of arguments pro TTIP can be set out such as increased level of economic activity 
and productivity gains, TTIP cannot serve as solution for all of the problems existing in 
Europe. Finally, he mentioned enhanced regulatory cooperation as being essential if the EU 
and the US wish to play a leading role in developing international regulations and standards 
based on the highest levels of protection. 
 gave a brief overview of the content of TTIP negotiations focusing on the 
medical devices sector. While TTIP will be an ambitious and balanced agreement dismantling 
both tariff and non-tariff barriers, in this area the main benefits are expected to come from the 
latter, as the existing tariffs on medical devices are already mostly zero. She highlighted the 
high level of transparency provided by COM in terms of TTIP. Among others the Advisory 
Group with several representatives from
 very diverse sectors, a number of events taking place 
during and after each round of talks with several hundred representatives of civil society 
attending as well as comprehensive materials on all aspects of the negotiations posted on the 
website. She em
phasized that no legal text is available yet regarding medical devices, 
pharmaceuticals and cosmetics regulatory aspects. Finally the most important possible 
elements for a medical devices annex in TTIP were explained such as Quality Management 
system Audits (QMS), Unique Device Identification (UDI) and interoperable databases as 
well as the Regulated Product Submission (RPS).  
After the panel discussions several questions were raised, among them: 
•  To what extent can the public debates influence the negotiations?  
•  Is further cooperation foreseen in new/emerging areas (''living agreement'')? 
•  Is the above mentioned study publicly available and what kind of methodology was 
followed in the analysis? 
 
On the first question 
 answered that basically the Commission follow the public 
debates but those do not focus on the aspects dealt in the technical discussions. As regards the 

possible cooperation in new areas, similarly to the pharmaceuticals, both Parties could co-
operate on new issues and consider developing disciplines and principles aimed at good 
regulatory practices specific to the medical device sector. Ms Bourguignon clarified that the 
results unveiled in the study are based on the comparison of the absolute number of annual 
recalls over a given period in the EU and the US and the study is available for the public. 
 

Document Outline